Yarrow Bioscience, Inc. Common Stock
YARW
38 hedge funds and large institutions have $1.1M invested in Yarrow Bioscience, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 11 reducing their positions, and 3 closing their positions.
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
3% more funds holding
Funds holding: 37 → 38 (+1)
0% less ownership
Funds ownership: 0.02% → 0.01% (-0%)
40% less capital invested
Capital invested by funds: $1.84M → $1.1M (-$738K)
73% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$64.1K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$9.79K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$4.2K |
| 4 |
SG
StoneX Group
New York
|
+$3K |
| 5 |
TFA
Tobias Financial Advisors
Plantation,
Florida
|
+$2.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DA
DSC Advisors
Chicago,
Illinois
|
-$244K |
| 2 |
VF
Virtu Financial
New York
|
-$14K |
| 3 |
Renaissance Technologies
New York
|
-$13.8K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$7.19K |
| 5 |
Jane Street
New York
|
-$6.99K |
YARW Hedge Fund Activity: Q4 2022 in Review
38 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Yarrow Bioscience, Inc. Common Stock (YARW) for Q4 2022, worth a combined $1.1M — down 40% from $1.84M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new YARW positions and 3 closed out — a net gain of 1 holder — while 3 added to existing stakes and 11 trimmed.
The largest buyer was Millennium Management, adding an estimated $64.1K. The largest seller was DSC Advisors, cutting an estimated $244K.
- 38 institutional investors held Yarrow Bioscience, Inc. Common Stock (YARW) as of Q4 2022, up from 37 in Q3 2022.
- Funds reported $1.1M of Yarrow Bioscience, Inc. Common Stock stock for Q4 2022, down 40% quarter-over-quarter.
- 4 funds opened new Yarrow Bioscience, Inc. Common Stock positions in Q4 2022 and 3 closed out, a net change of +1 holder.
- The largest Yarrow Bioscience, Inc. Common Stock buyer in Q4 2022 was Millennium Management, an estimated $64.1K added.
- The largest Yarrow Bioscience, Inc. Common Stock seller in Q4 2022 was DSC Advisors, an estimated $244K sold.
Based on aggregated 13F filings for Q4 2022.